Abstract YO8
Case summary
Carcinosarcoma of the breast is an aggressive, malignant biphasic neoplasm. It is comprised of carcinomatous and sarcomatous elements and accounts for 0.08–0.2% of all breast malignancies. Due to the rarity of this disease, it remains poorly understood and infrequently reported. Here we present a case of a 38 year old Filipino woman with a 2 month history of mass in her left breast. Progressive enlargement of the mass warranted excisional biopsy and revealed high grade carcinoma. Metastatic work up were unremarkable. Thus, the patient underwent modified radical mastectomy. Histopathology revealed metaplastic carcinoma, carcinosarcoma type with background of ductal carcinoma in-situ, nuclear grade 1 with no definite lymphovascular space invasion. All 12 lymph nodes were negative for tumor but nipple was positive for tumor. Immunohistochemistry report revealed positive for ER, PR and negative for HER2/Neu overexpression. Furthermore, tumor cells were positive for pancytokeratin in carcinomatous areas and vimentin in sarcomatous areas. The patient is receiving hormonal therapy and remains to be asymptomatic and on close surveillance.
A multi-disciplinary approach with an accurate diagnosis are essential to optimally tailor potentially effective treatment options in this kind of patients. To date, there is no standardized treatment protocol for the management of carcinosarcoma of the breast. Long-term follow-up is important because of the increased likelihood of local recurrence and metastasis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract